Business Context and Reporting Period
Company: Oncolytics Biotech Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fiscal Year Ended December 31, 2007 (Annual Report included as Exhibit 1)
Date of Filing: April 7, 2008
Business Overview: Oncolytics is a development-stage biopharmaceutical company focused on the discovery and development of REOLYSIN®, a proprietary formulation of the human reovirus, as a novel cancer therapeutic. The company has no commercial product sales and relies on equity financing to fund research and development (R&D).
Key Financial Metrics (Fiscal Year 2007)
| Metric | 2007 | 2006 |
|---|---|---|
| Revenue | $0 | $0 |
| Interest Income | $1,211,744 | $1,233,809 |
| Net Loss | $(15,642,191) | $(14,297,524) |
| Loss Per Share (Basic & Diluted) | $(0.39) | $(0.39) |
| Total Assets | $30,781,857 | $33,565,692 |
| Cash and Cash Equivalents | $6,715,096 | $3,491,511 |
| Short-term Investments | $18,498,733 | $24,122,237 |
| Total Liquidity (Cash + Investments) | $25,213,829 | $27,613,748 |
| Working Capital | $22,732,987 | $25,719,870 |
| Long-term Debt | $0 | $150,000 |
| Accumulated Deficit | $(80,522,257) | $(65,030,066) |
Note: The $150,000 Alberta Heritage Foundation loan was reclassified to fair value and eliminated from liabilities in 2007 due to the adoption of new financial instrument accounting standards, with a corresponding adjustment to the deficit.
Material Changes vs. Prior Period
- Financing Activity: In February 2007, the company completed a public offering of 4,600,000 units at $3.00 per unit, raising gross proceeds of $13.8 million (net proceeds of $12.06 million). This significantly bolstered cash reserves compared to 2006.
- Operating Expenses: Total R&D expenses increased to $11.3 million in 2007 from $10.5 million in 2006. This increase was driven primarily by higher clinical trial expenses ($3.9 million vs. $2.7 million) due to the expansion of the clinical program.
- Cash Usage: Cash used in operating activities was $13.6 million in 2007, consistent with the estimated monthly burn rate of approximately $1.4 million.
- Debt Elimination: The company no longer carries the $150,000 long-term debt from the Alberta Heritage Foundation on its balance sheet as of December 31, 2007, following an accounting policy change.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Progress: 2007 was the company's most active year, with the initiation of four new trials and positive interim results from Phase I/II studies. Key milestones include meeting criteria to proceed to full enrollment (52 patients) in the U.S. Phase II sarcoma trial.
- 2008 Expectations: Management expects to conclude enrollment in several Phase II trials in 2008. The company anticipates monthly cash usage will increase to approximately $1.66 million in 2008.
- Liquidity: Based on current resources, management estimates cash reserves are sufficient to fund operations well into 2009.
- Manufacturing: The company successfully scaled manufacturing to the 40-litre level and is testing the 100-litre level to prepare for commercial demand.
Risks and Contingencies
- Development Risk: As a development-stage company, Oncolytics has no operating revenues and a history of losses. There is no assurance that REOLYSIN® will prove safe or effective in humans or obtain regulatory approval.
- Capital Requirements: The company may require additional financing in the future. There is no assurance that additional capital will be available on acceptable terms.
- Manufacturing Dependence: The company currently relies on a single toll manufacturer in the U.K. for clinical supplies. Disruption of this supply could delay clinical trials.
- Product Liability: The company currently does not have product liability insurance, which could inhibit commercialization if claims arise.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $25.2 million liquidity position against the projected $1.66 million monthly burn rate for 2008.
- Clinical Milestones: Monitor the results of the U.S. Phase II sarcoma trial and the U.K. combination therapy trials, as these are critical for future valuation and funding.
- Regulatory Status: Track FDA and MHRA approvals for ongoing and planned trials, including the NCI-sponsored melanoma and ovarian cancer trials.
- Manufacturing Scale-up: Confirm the successful transfer of the 40-litre manufacturing process to the U.S. toll manufacturer and the results of 100-litre scale-up studies.
- Equity Dilution: Note the existence of 4.22 million warrants and 3.87 million stock options outstanding, which could dilute existing shareholders upon exercise.